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Most sarcomere gene mutations that cause hypertrophic cardiomyopathy are missense 
alleles that encode dominant negative proteins. The potential exceptions are mutations 
in the MYBPC3 gene (encoding cardiac myosin-binding protein C, MyBP-C), which 
frequently encode truncated proteins, suggesting that they may act as null alleles 
resulting in haploinsufficiency. We compared left ventricular muscle from patients 
undergoing surgical myectomy with samples from donor hearts. Nine of 37 myectomy 
samples had mutations in MYBPC3: two missense alleles (Glu258Lys, Arg502Trp) and 
seven premature terminations. No specific truncated MyBP-C peptides were detected in 
whole muscle homogenates of HCM tissue. However, the overall level of MyBP-C in 
myofibrils was significantly reduced (p<0.0005) in tissue containing either a truncation 
or missense MyBP-C mutation: 0.76±0.03 compared with 1.00±0.05 in donor and 
1.01±0.06 in non-MYBPC3 mutant myectomies. The absence of any detectable truncated 
MyBP-C argues against its incorporation in the myofibre and any dominant negative 
effect.  In contrast, the lowered relative level of full length protein argues strongly for 
haploinsufficiency as the disease mechanism for both truncation and missense MYBPC3 
mutations.  
3 
Myosin binding protein C (MyBP-C) is a component of the thick filaments of striated 
muscles. The human cardiac muscle isoform, encoded by MYBPC3, is composed of 11 
globular domains, eight with homology to IgI and three with fibronectin III
1
 (Figure 1).   
MyBP-C is likely to have both structural and regulatory roles within the sarcomere and recent 
data have suggested that MyBP-C has a role in relaxation and stretch activation
2, 3
. The 
physiological importance of MyBP-C has been further highlighted with the discovery of 
mutations in MYBPC3 as the most commonly identified cause of hypertrophic 
cardiomyopathy (HCM), typically being found in ~20-25% of patients screened; more than 
150 different mutations have been reported
4, 5
.  In striking contrast to all other HCM disease-
genes, about two thirds of MYBPC3 mutations are predicted to generate a truncated protein 
product. At present it is not known if the autosomal dominant nature of the MYBPC3 
mutations results from haploinsufficiency (indicating that functional loss of one copy of the 
gene cannot be compensated) or a poison peptide effect (by which the mutant proteins 
interfere with normal sarcomere function). Functional studies on HCM mutants of other 
proteins have given clear evidence of a poison peptide effect
6
.  Published studies on the heart 
muscle of individual patients with different MYBPC3 truncation mutations did not find 
truncated protein but one study suggested reduced MyBP-C content
7-9
 Data from transgenic 
mouse models that overexpress truncated cMyBP-C have been conflicting with support for 
both mutant protein incorporation and haploinsufficiency10, 11.  Mice with both alleles of 
MyBP-C knocked out are viable12, 13; in one model, heterozygous null mice show a slight 
decrease in MyBPC expression and a late-onset hypertrophy phenotype, consistent with a 
haploinsufficiency mechanism12.  In this report we have searched for truncated peptides and 
reduced MyBP-C quantity in myofibrils from control and affected human heart tissue and find 
a consistently lower MyBP-C expression in the patients with either truncation or missense 
MYBPC3 mutations. 
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Materials and Methods 
We obtained human heart muscle from donor hearts and interventicular septum from HCM 
patients at surgical myectomy.  Genotyping and mRNA analysis was by standard methods.  
MyBP-C protein was detected in muscle homogenates and myofibrillar fractions using an 
antibody specific to the N-terminal region of MyBP-C and the MyBP-C content was 
quantified relative to the actin content using an anti-actin antibody.  Details of the methods, 
and clinical details, are given in full in the online supplement. 
 
Results 
 We screened for MYBPC3 mutations in a series of left ventricular septum samples 
from HCM patients undergoing septal myectomy to relieve left ventricular outflow tract 
obstruction. In nine of the 39 patients, mutations in MYBPC3, with convincing evidence that 
they were responsible for HCM, were identified (Figure 1).  Two carried previously described 
missense alleles Glu258Lys (sample code M10) and Arg502Trp (MA); seven had premature 
terminations, truncating in domains C3 (same mutation present in M8, MI, MT, predicted 
molecular weight 52 kDa), C5 (M9, 90 kDa), C7 (M15, 97kDa; M25, 114 kDa), and C10 
(M6, 140 kDa). 
 Immunoblots were carried out on whole tissue homogenates from the myectomy 
samples using an antibody specific to the N-terminus (C0-C2) of MyBP-C (see Online Figure 
1).  At moderate loading (2!g tissue), MyBP-C was detected as a single band (Figure 1B). We 
did not observe any bands corresponding to the expected truncated protein in M6, M8, M9, 
M15, M25, MI or MT at moderate (Figure 1B) or high (Online Figure 2) loading. Loading 
tests indicated that the antibody could detect a concentration of less than 3% of the main 
bands. 
 The quantity of MyBP-C in myofibrils was determined in myectomy samples and 
compared with non-failing donor heart muscle (Figure 2).  The quantity of MyBP-C relative 
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to actin was consistent between donor heart samples and the mean ratio was used to normalise 
all of the data. An MyBP-C/actin content significantly lower than donor was found in every 
myectomy sample containing a MYBPC3 mutation, including the two missense mutations 
(Figure 2B and Online Figure 3, Table 2). The mean MyBP-C/actin ratio in myofibrils of all 
samples with MYBPC3 mutations was 24±3% lower than donor tissue but the ratio was 
unaltered in myectomy samples that did not have a MYBPC3 mutation  (myectomy/donor= 
1.01±0.06).  
 In order to examine whether reduced amounts of mutant message contributed to the 
lower total MyBP-C protein content, wild type/mutant MYBPC3 mRNA ratios were measured 
in four of the samples using a real time PCR assay with allele-specific primers (Figure 2C). A 
moderate decrease in the relative abundance of the mutant transcript in comparison with the 
wild type was found in three samples, including the missense mutation sample M10.  
6 
Discussion 
 We have been able to systematically assess the effect of both truncation and missense 
HCM-causing MYBPC3 mutations in human heart muscle by studying a series of 9 samples 
obtained from patients undergoing surgical myectomy in comparison with donor heart and 
myectomy samples without a MYBPC3 mutation. In samples with MYBPC3 truncation 
mutations we show that no truncated MyBP-C proteins are detectable, either incorporated (as 
determined by analysis of myofibril fractions) or indeed unincorporated into the sarcomere 
(from analysis of homogenates). In analysis of all heart samples of patients bearing MYBPC3 
mutations, we find a 24% lower MyBP-C content, thus arguing strongly for 
haploinsufficiency as the disease mechanism for both truncation and missense mutations. This 
agrees with, and extends, certain earlier observations
7-9
. For the truncation mutants, the 
measured modest reductions in mRNA (Figure 2C) cannot account for the undetectable levels 
of mutant MyBP-C protein and thus degradation of the truncated protein is likely, possibly via 
the ubiquitin-proteasome system as earlier proposed
14
. The presence of normal MyBP-C 
mRNA from the remaining wild type allele is apparently not sufficient to yield a full 
complement of MyBP-C protein; this is in contrast to some other contractile proteins, for 
example a heterozygous !-tropomyosin knockout mouse has the normal level of protein in the 
heart
15
. Our surprising finding that missense mutations can cause MyBP-C haploinsufficiency 
may also be explained by proteolysis of the mutant protein (as reported for one 
heterologously expressed MYBPC3 missense mutant
16
) although a modest reduction in mutant 
mRNA (as suggested by the M10 data in Figure 2C) could also account for the reduced full 
length protein. 
 Although haploinsufficiency has not been observed with mutations in other HCM 
genes, we propose that it accounts for the pathogenic effect of MYBPC3 mutations. 
Functional studies, in which MyBP-C has been partially extracted from fiber preparations to a 
7 
similar extent to the reduction observed in myectomy tissue, suggest that the observed 
reduction in protein content is sufficient to have a significant effect on contractility
17, 18
. The 
depletion of MyBP-C protein in different samples is not equivelent and we suggest this may 
contribute to the observed spectrum of disease severity. 
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Figure Legends  
 
Figure 1   Location of MyBP-C mutations and detection of MyBP-C protein in muscle 
homogenates. 
A  Domain structure of MyBP-C showing the location of the MyBP-C mutations detected in 
the myectomy samples. 
B  Whole homogenates of heart muscle probed with anti MyBP-C.  2!g of whole muscle 
homogenate was separated by SDS-PAGE and MyBP-C was detected using a rabbit 
polyclonal antibody.  Arrows indicate the predicted position of truncated peptides for M25 
(114kDa), M15 (97kDa), M9 (90kDa) and M8 (52kDa).  MA and M10 are missense 
mutations, M5 has no MyBP-C mutation.  A single c.140kDa band was observed in all 
myectomy samples, including those with predicted MyBP-C truncations. 
 
Figure 2  MyBP-C content in myofibrillar fraction 
A Typical immunoblot, probed with anti MyBP-C and anti-actin.  MyBP-C band is reduced 
relative to actin in M25, which has a MYBPC3 mutation. 
B The normalised MyBP-C: actin ratio for individual samples.  Each bar represents the mean 
and standard error of 3-9 separate measurements (see Online Figure 2).  Black bars: donor 
heart samples, grey bars: myectomy samples, red bars: myectomy samples with identified 
MYBPC3 mutations.  MyBP-C content in every sample was significantly less than 1 
determined by t-test (see Online Table 2).    indicates  missense mutation. 
C The proportions of wild type (solid bars) and mutant (hatched bars) transcripts present in 
total MYBPC3 mRNA measured using a real time PCR assay with allele-specific primers. 
Error bars indicate SEM (n=4). Wild type mRNA in samples M9, M10 and M15 was 
11 
significantly greater than mutant MYBPC3 mRNA (* p<0.05) whereas the difference in the 
M6 sample was not significant (ns). 
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Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic 
cardiomyopathy through haploinsufficiency. 
S. Marston, O. Copeland, A. Jacques, K. Livesey, V. Tsang, P.M. Elliott, W.J. McKenna, S. 
Jalilzadeh, S. Carballo, C. Redwood, H. Watkins
 
 
SUPPLEMENTARY MATERIAL: METHODS 
 
Collection and Storage of Human Myocardium 
Hypertrophic Cardiomyopathy   Human myocardial samples were obtained from patients with 
hypertrophic cardiomyopathy undergoing surgical septal myectomy for relief of left 
ventricular outflow tract obstruction. The samples were frozen in liquid nitrogen and stored 
for later use. Local ethical approval was obtained from University College London Hospitals 
and Royal Brompton and Harefield ethics committees for collection of tissue samples.  The 
HCM patients clinical phenotypes were characterised by obtaining detailed clinical histories 
and examinations. All patients had cardiac investigations including, 12-lead ECG, chest X-
ray, holter monitor, cardiopulmonary exercise test, two-dimensional transthoracic 
echocardiography, transoesophageal echocardiography, cardiac catheterisation and coronary 
angiography ( Online Table 1) 
1, 2
.  
Non-Failing donor heart muscle. Tissue samples were supplied by Prof. C Dos Remedios, 
University of Sydney, Australia.  Ethical approval was obtained from The Brompton, 
Harefield & NHLI, London and St Vincent’s Hospital, Sydney.  The investigation conformed 
with the principles outlined in the Declaration of Helsinki. Non-failing heart tissue (donor) 
was obtained from donor hearts where no suitable transplant recipient was found.  These were 
obtained from patients with no history of cardiac disease, a normal cardiac examination, 
normal ECG and normal ventricular function on echocardiography within 24 hours of heart 
explantation.  Myocardium was immediately frozen in liquid nitrogen and stored for later 
analysis.  Clinical and functional characteristics of troponin from these samples has been 
previously reported 
3
. 
Genotyping of HCM Patients 
Blood samples were collected and genetic analysis performed on the genomic DNA extracted. 
Local ethical approval was obtained for collection of blood samples; mutation screening of 
coding regions and splice sites of the MYBPC3 gene (exon 1-34) was undertaken using 'Hi-res 
Melting' analysis (LightScanner) and bi-directional fluorescent sequencing using big dye 
terminators and ABI3730. 
 
Preparation of whole muscle homogenates and myofibrillar fraction from human heart 
muscle 
Human heart samples (50mg) were removed from liquid nitrogen and immediately pulverised 
in a lN2 cooled percussion mortar. Pulverised human heart muscle was manually homogenised 
in 1.5ml of a wash buffer containing 5mM NaH2PO4, 5mM Na2HPO4 pH 7.0, 0.1M NaCl, 
5mM MgCl2, 0.5mM EGTA, 0.1% Triton X-100 and 5mM DTT with 2µg/ml each of the 
protease inhibitors E64, chymostatin, leupeptin and pepstatin A.  This whole homogenate was 
used to assay for truncated peptides.  For myofibrils the homogenate was then centrifuged at 
16,500xg for 5 minutes and the supernatant discarded.  The wash-homogenisation-
sedimentaion step was repeated three more times until the pellet was pale yellow. The 
myofibrillar pellet was then dissolved in SDS-gel solution for analysis by SDS-PAGE.   
 
Western blotting. 
The MyBP-C content in whole muscle homogenates and in the myofibrillar fraction was 
measured in western blots of SDS-PAGE.   Gel-electrophoresed proteins were transferred to 
nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Biotech, RPN 303D) with a 
Hoeffer semi-dry electroblotter (Semi-phor TE70) at 6mA and 200 mV for 2 hours at 4°C. 
Membranes were blocked for 1 hour at room temperature in blocking buffer [1% dried milk 
powder, 0.1% Tween 20 and 1 x phosphate buffered saline (137 mM NaCl, 27 mM KCL, 4.3 
mM Na2HPO4.7H2O, 1.4 mM KH2PO4, pH 7.3)].  Blots were incubated overnight in rabbit 
polyclonal antibody to MyBP-C at 1/20,000 (gift from Samantha Harris 
4
) normalised to 
tissue quantity by including a rabbit polyclonal anti-actin antibody (Sigma A2066, 1/2000).  
MyBP-C and actin were detected using anti-rabbit HRP and ECL and visualised with a cooled 
CCD camera.  12-bit TIFF images were analysed with GeneQuant software (Syngene).  Tests 
with recombinant MyBP-C fragments showed that the antibody cross-reacted specifically 
with the N-terminal region (C0-C2, see Online Figure 1). 
 
 mRNA quantitation 
RNA was extracted from 30 mg of frozen myectomy tissue using the RNeasy Fibrous Tissue 
kit (Qiagen) according to manufacturers’ instructions. Reverse transcription was carried out 
using oligo dT primers. The following Taqman primers specific for the wild type (FAM 
labelled) and mutant (YAK labelled) allele for samples M6, M9, M10 and M15 were 
synthesised: 
M6:  5’-CGCCTGGAGGTGCGAGTGCC (wild type) 
5’-CGCCTGGAGGTGTGAGTGCC (mutant) 
M9:  5’-CCTGCAGTACAGTTGGGAGCCGC (wild type) 
5’-CTGCACAGTACAGGTTGGGAGCCGC (mutant) 
M10:  5’-CTCACTGTCCACGAGGCCTGGGCA (wild type) 
5’-CTCACTGTCCACAAGGCCTGGGCA (mutant) 
M15 5’-TCGCTGGGGGGACCGATAGGC (wild type) 
5’-GGTTCGCTGGGGGTCCGATAGGC (mutant) 
 
qPCR carried out using a Roche 480 Lightcycler. The difference in the number of cycles 
between wild type and mutant to reach threshold (!Ct method) was used to calculate the ratio 
of wild type to mutant mRNA with the assumption that the efficiencies of the wild and mutant 
reactions were identical.  
 
SUPPLEMENTARY MATERIAL: RESULTS 
 
Online Figure 1 
Demonstration of specificity of the MyBP-C antibody for the N-terminal domains C0-C2 
upstream of all predicted chain terminations. 
 
 
 
 
 
Online Figure 2 
Western blot of 15!g of whole muscle homogenate separated by SDS-PAGE and probed with 
antibody to MyBP-C. Bands at 95, 60 and 45kDa represent non-specific labelling of 
myofibrillar proteins or breakdown of MyBP-C and were the same in all samples.  Arrows 
indicate the predicted position of truncated peptides in M25, M15, M9 and M8. 
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Online Figure 3 
Complete dataset of MyBP-C content determinations in myectomy samples. 
Means and standard errors of these data are plotted in Figure 2C. Red asterisk indicates 
missense mutations. 
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Online Table 2 
Statistical analysis of data.   
MyBP-C content is significantly less than the donor control (=1, t-test) and in most cases 
significantly greater than 0.5. 
 
Sample Quantity 
relative to 
NF ± sem
 
n P single group v.s. 0.5 P single group v.s. 1.0 
M6 0.77±0.05 9 0.0006 0.002 
M8 0.68±0.07 5 .07 .01 
M9 0.81±0.05 5 0.004 0.028 
M10 0.85±0.03 9 <0.0001 0.002 
M15 0.65±0.04 9 <.0001 .006 
M25 0.65±0.05 3 .088 .02 
MA 0.82±0.05 7 .0004 .01 
MI 0.83±0.04 8 <0.0001 0.003 
MT 0.74±0.03 8 0.0002 0.0001 
 
 
 
Online Figure 4 
 
Determination of the transcripts produced by the Glu258Lys mutation 
An earlier report found that the Glu258Lys mutation has an effect on splicing in that two 
transcripts were shown to be generated by this mutation in peripheral blood lymphocyte 
cDNA, one full length bearing the expected missense mutation and the other in which exon 6 
is skipped
5
. |In order to test whether the Glu258Lys mutation affects splicing in the heart, 
cDNA was amplified by PCR using the MYBPC3 primers 5’-
ACTGCAGAACATATGATTGGCCTCTTCGTGATGCGG and 5’-
GCTGGAGGTGGTCGGCGGATCAGTGATAGCCAT; this was predicted to give a 417bp 
product for the normally spliced transcript and a 249bp product if exon 6 were skipped. Our 
data show no evidence of the 249bp product suggesting that this mutation generates only a 
full length transcript including the Glu258 mutation in the myocardium. 
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